Trust signals
FormBlends Medical Team
May 29, 2026
GRADE-aligned; sources listed
FormBlends sells peptide products; disclosures in footer
Key Takeaways
- BPC-157 is a 15-amino-acid synthetic peptide fragment derived from a human gastric protein; its molecular weight is approximately 1,419.5 Da and its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
- All efficacy evidence is from animal models (rodent predominantly) or in vitro; no peer-reviewed, randomized, placebo-controlled human trial has been published confirming clinical outcomes for musculoskeletal repair or systemic benefits.
- Adding 5 mL of bacteriostatic water to a 5 mg vial yields 1,000 mcg/mL, making a 250 mcg dose exactly 0.25 mL -- the easiest to measure on a standard 1 mL insulin syringe.
- Reconstituted BPC-157 in bacteriostatic water is commonly regarded as stable for up to 4 weeks at 2-8°C; lyophilized powder kept at -20°C lasts considerably longer but degrades meaningfully with repeated freeze-thaw cycling.
- The pro-angiogenic mechanism that underlies BPC-157's proposed healing effects is also the reason a theoretical tumor-promotion concern exists; this has not been observed in published animal toxicology at tested doses, but human long-term safety data are absent.
What is BPC-157 and what does the evidence actually support?
Table of Contents
- Evidence ledger: what the research actually shows
- Mechanism with numbers
- How to reconstitute BPC-157 step by step
- How to reconstitute a BPC-157 / TB-500 blend
- Dosing table and injection technique
- Stability, storage, and what degradation looks like
- What most pages get wrong about BPC-157 injections
- Head-to-head: BPC-157 vs. alternatives
- COA and label literacy: how to verify what you bought
- FAQ
- Sources
Evidence Ledger: What the Research Actually Shows
| Claim | Best evidence type | Effect direction | Confidence |
|---|---|---|---|
| Accelerates tendon-to-bone healing | Rodent RCT (multiple labs) | Positive in animals | Low (no human data) |
| Promotes GI mucosal repair | Rodent/in vitro; originally isolated from gastric juice protein | Positive in animals | Low |
| Upregulates VEGFR2 expression | In vitro cell culture, confirmed in several papers | Positive (mechanistic) | Moderate (mechanism only) |
| Reduces NSAID-induced gut damage | Rodent models; one small human gastric mucosal pilot (unpublished full data) | Positive in animals | Very low (human) |
| Systemic safety in humans | No completed published RCT | Unknown | Very low |
| Oral bioavailability for systemic effect | Animal GI-endpoint studies only; no PK data in humans | Unclear for systemic use | Very low |
Confidence ratings follow GRADE principles: High = multiple consistent human RCTs; Moderate = one good human trial or consistent animal RCTs; Low = animal data only; Very low = mechanistic or anecdotal only.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Mechanism With Numbers
BPC-157 (Body Protection Compound-157) is a pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It does not occur freely in human gastric juice; it is synthesized as a fragment derived from the larger gastric protein BPC.
Primary proposed pathway: BPC-157 upregulates expression of vascular endothelial growth factor receptor 2 (VEGFR2, also called KDR/Flk-1). In in vitro fibroblast and endothelial cell studies, this is associated with increased cell migration and tube formation -- both prerequisites for angiogenesis and tissue remodeling. Sikiric et al. and subsequent groups have documented this VEGFR2 upregulation across multiple cell-culture platforms, though translating receptor upregulation in a petri dish to clinical healing in a human is several inferential steps.
Nitric oxide (NO) modulation: BPC-157 is proposed to interact with the NO system, specifically modulating eNOS activity. In rodent models of hypertension and stomach lesion, this interaction appears to influence local vascular tone. The exact binding target has not been identified at a crystallographic level.
What mechanism does NOT prove: Upregulating VEGFR2 in cell culture does not confirm that subcutaneous injection of 250 mcg in a human produces sufficient local peptide concentration at a tendon injury site to replicate the effect. Pharmacokinetic data for subcutaneous BPC-157 in humans (half-life, Cmax, tissue distribution) have not been published in peer-reviewed form. The mechanism is biologically plausible, not clinically validated.
How to Reconstitute BPC-157 Step by Step
Equipment checklist
- BPC-157 lyophilized vial (commonly 2 mg or 5 mg)
- Bacteriostatic water for injection (multi-dose vial)
- Two 1 mL or 3 mL syringes with 23- or 25-gauge drawing needle
- 29- or 31-gauge insulin syringes for injection
- Alcohol swabs
- Sharps container
Reconstitution protocol
- Allow the lyophilized vial to reach room temperature (15-30 minutes). This prevents condensation from forming inside when you puncture the stopper.
- Swab both the peptide vial stopper and the BAC water vial stopper with a fresh alcohol swab. Allow to air dry for 10 seconds.
- Draw the target volume of BAC water into the drawing syringe.
- Insert the needle into the peptide vial at an angle so the liquid runs down the inside glass wall, not directly onto the powder cake. Blasting liquid onto lyophilized peptide can shear peptide bonds and reduce potency.
- Remove the syringe and swirl gently for 15-20 seconds. Do not shake or vortex. The solution should become clear and colorless within 30-60 seconds.
- If the solution is cloudy, contains visible particles, or has a yellow tint, discard it.
- Label the vial with the date of reconstitution and the concentration.
Reconstitution math table (5 mg vial)
For a 2 mg vial, adding 2 mL BAC water gives 1,000 mcg/mL, so a 250 mcg dose is 0.25 mL. This maintains the same easy-to-read volume.
How to Reconstitute a BPC-157 / TB-500 Blend
TB-500 is a synthetic analog of Thymosin Beta-4 (TB4), a 43-amino-acid actin-sequestering protein. It is commonly combined with BPC-157 in pre-blended lyophilized products or as separate vials drawn into the same syringe.
Pre-blended lyophilized vial
Treat a pre-blended vial exactly as a single-peptide vial. Use the same BAC water technique. The concentration printed on the label (e.g., 5 mg BPC-157 + 5 mg TB-500) is the total peptide content, not total volume. Calculate concentrations and doses for each component separately.
Combining two separately reconstituted vials
- Reconstitute each vial individually with a small volume of BAC water (e.g., 1 mL each) to ensure full dissolution.
- Draw the desired dose volume of each reconstituted solution into the same injection syringe immediately before injection.
- Inject immediately; do not pool and store combined solutions long-term in one vial unless it is a purpose-built blended product, because you do not have a validated stability window for the combination.
Dosing Table and Injection Technique
| Protocol type | Typical dose range | Frequency | Route | Evidence basis |
|---|---|---|---|---|
| Animal studies (rodent) | 10-200 mcg/kg | Once daily | Intraperitoneal or subcut | Published rodent RCTs |
| Human self-reported (low) | 200 mcg/day | Once daily | Subcutaneous | Anecdotal/forum |
| Human self-reported (common) | 250-500 mcg/day | Once or twice daily | Subcutaneous | Anecdotal/forum |
| Human self-reported (high) | 750-1,000 mcg/day | Split doses | Subcutaneous | Anecdotal only |
Subcutaneous injection technique
- Wash hands thoroughly. Use alcohol swabs on the injection site and the vial stopper.
- Draw the calculated dose volume into the insulin syringe. Tap out air bubbles and expel them.
- Pinch a fold of skin at the chosen site (abdomen, lateral thigh, or near the injury region). The abdomen 2 inches from the navel is the most common site.
- Insert the needle at a 45-degree angle for thin individuals or 90 degrees for those with more subcutaneous tissue. For a 0.5-inch needle at 90 degrees, the needle stays subcutaneous in most adults.
- Inject slowly over 5-10 seconds. Withdraw smoothly.
- Rotate injection sites with each administration to prevent lipodystrophy or nodule formation.
- Dispose of needle immediately in a sharps container.
Stability, Storage, and What Degradation Looks Like
| Form | Storage condition | General stability estimate | Notes |
|---|---|---|---|
| Lyophilized powder (sealed) | -20°C, dark | Months to years | Best long-term option; minimize freeze-thaw cycles |
| Lyophilized powder (sealed) | 2-8°C refrigerator | Weeks to a few months | Acceptable for near-term use |
| Reconstituted in BAC water | 2-8°C refrigerator | Up to approximately 4 weeks | Community consensus; no published validated stability data |
| Reconstituted in sterile water | 2-8°C refrigerator | Use within 24 hours | No antimicrobial preservative |
| Any form | Room temperature, light exposure | Days or less | Peptide bonds hydrolyze; oxidation accelerates degradation |
Signs of degradation to discard on sight: cloudiness or particulates in solution, yellow or brown discoloration, unusual odor, any visible mold or film at the stopper. A clear, colorless, particle-free solution is necessary but not sufficient to confirm potency -- silent chemical degradation (oxidation of methionine-adjacent residues, deamidation) can occur without visible change.
What Most Pages Get Wrong About BPC-157 Injections
This is the section commodity pages skip.
1. "Near the injury" is not a validated pharmacokinetic principle for humans
Animal studies, particularly early Sikiric lab work, often administered BPC-157 intraperitoneally at relatively high doses per kg. The claim that subcutaneous injection near a human tendon injury produces meaningful local peptide concentrations has not been tested with human pharmacokinetic studies. We do not have published Tmax, Cmax, or tissue-distribution data for subcutaneous BPC-157 in humans. The proximity rationale is intuitive but unvalidated.
2. Purity claims on COAs are frequently for HPLC area percent, not actual mass purity
An HPLC purity of "greater than 98%" means 98% of the UV-absorbing peaks in the chromatogram are the target peptide, assuming the response factor of impurities equals the target. It does not account for peptide-inactive fragments that co-elute, water content (which can be 10-15% of lyophilized peptide mass), or residual synthesis reagents (TFA salt, acetic acid) that affect actual active peptide per mg. A TFA-heavy salt form delivers less molar peptide per listed milligram than the acetate form. Always ask whether the listed mass is the peptide free acid, TFA salt, or acetate form.
3. The 4-week refrigerator stability window is community convention, not validated data
No published, peer-reviewed stability study has confirmed that reconstituted BPC-157 in BAC water at 4°C retains X% potency at 4 weeks. The figure circulates in peptide communities and is likely conservative and reasonable, but it is not the same as a validated pharmaceutical stability study. If you want confidence in what you're injecting, use within 2 weeks and keep it dark and cold.
4. Benzyl alcohol in BAC water has a dose limit
Bacteriostatic water contains 0.9% w/v benzyl alcohol. The WHO acceptable daily intake for benzyl alcohol by injection is generally cited at approximately 5 mg/kg/day. At typical peptide injection volumes (0.25-0.5 mL per injection), benzyl alcohol exposure is well below this threshold. However, if you are injecting multiple peptide compounds daily from BAC water-reconstituted vials, the accumulation should be considered, particularly in smaller individuals.
Head-to-Head: BPC-157 vs. Alternatives
| Comparison | BPC-157 (injection) | Alternative | Where BPC-157 wins | Where BPC-157 loses |
|---|---|---|---|---|
| vs. TB-500 | 15-AA, VEGFR2 upregulation, GI and tendon data | TB-500 (Thymosin Beta-4 analog): actin sequestration, anti-inflammatory, cardiac and muscle data in animals | More tendon/ligament rodent data; GI repair data | TB-500 has more cardiac repair animal data; two compounds often blended because mechanisms differ |
| vs. PRP injection | Synthetic peptide, no human RCT for musculoskeletal | Platelet-rich plasma: autologous, multiple human RCTs for tendinopathy (mixed but existing human evidence) | Cost, convenience, no blood draw required | PRP has actual human clinical trial data; BPC-157 has none |
| vs. Corticosteroid injection | Proposed regenerative; animal data only | Corticosteroid (e.g., triamcinolone): anti-inflammatory, strong human RCT evidence for short-term pain reduction | No documented cartilage-thinning or tendon-weakening risk (in animal data) | Corticosteroids have documented human RCT efficacy for pain; BPC-157 has no human pain RCT |
| vs. Oral NSAIDs | Injectable, no GI irritation from the compound itself | Ibuprofen/naproxen: well-characterized human RCT efficacy and safety profiles | Proposed GI-protective rather than GI-damaging | NSAIDs have decades of human safety/efficacy data; BPC-157 has none in humans |
COA and Label Literacy: How to Verify What You Bought
A Certificate of Analysis (COA) is the primary quality document. Here is what to demand and how to interpret it.
| Test | What to look for | Red flag |
|---|---|---|
| HPLC purity | Greater than 98%, with method stated (C18 column, UV 220 nm) | No method stated; result only says "greater than 95%" |
| Mass spectrometry (MS/ESI) | Molecular ion confirming 1419.5 Da (free acid) or the stated salt form MW | No MS data; only HPLC shown |
| Water content | Karl Fischer titration result less than 8-10% for lyophilized powder | No water content listed; high water content inflates apparent mg count |
| Residual TFA | Less than 0.1% TFA by ion chromatography or NMR | No TFA test; TFA salt form not disclosed |
| Sterility / endotoxin | LAL endotoxin less than 1 EU/mg; sterility per USP or equivalent | No endotoxin test at all |
| Issuing laboratory | Named third-party lab, not "internal QC" | COA issued by the seller's own lab with no accreditation stated |
FAQ
How do you reconstitute BPC-157?
Add bacteriostatic water slowly down the side of the vial, not directly onto the lyophilized powder. For a 5 mg vial, adding 2.5 mL BAC water yields 2,000 mcg/mL; adding 5 mL yields 1,000 mcg/mL. Swirl gently, never vortex. The solution should be clear and colorless.
What syringe do you use for BPC-157 injections?
A 29- or 31-gauge insulin syringe (0.3 mL or 1 mL volume) is standard for subcutaneous injection. The 0.5-inch needle length is adequate for subcut administration near the site of injury.
How much BAC water do you add to a 5 mg BPC-157 vial?
Adding 2.5 mL gives a concentration of 2,000 mcg/mL, so a 250 mcg dose requires 0.125 mL. Adding 5 mL gives 1,000 mcg/mL, so a 250 mcg dose requires 0.25 mL. The 5 mL dilution is easier to measure accurately on an insulin syringe.
Can you mix BPC-157 and TB-500 in the same vial?
Yes, a BPC-157/TB-500 blend can be reconstituted in one vial using BAC water. Reconstitute each lyophilized compound separately with a small volume first, then combine, or purchase a pre-blended lyophilized product. Both are stable in BAC water at 4°C for similar durations. There are no published incompatibility data, but no known chemical interaction either.
Where do you inject BPC-157?
Subcutaneous injection near the injury site is the approach used in most self-reported protocols. Animal studies used both intraperitoneal and subcutaneous routes. Inject into pinched skin at the abdomen, lateral thigh, or near the affected area. Rotate sites to avoid lipodystrophy.
What is the typical BPC-157 dose?
Animal studies typically used doses in the range of 10 mcg/kg to 200 mcg/kg. Human self-reported protocols commonly use 200-500 mcg per injection once or twice daily. No human clinical trial has established an evidence-based dose. Use the lowest dose that is practical to measure accurately.
How long is reconstituted BPC-157 stable in the refrigerator?
Reconstituted BPC-157 in BAC water is generally considered stable for up to 4 weeks when stored at 2-8°C and protected from light. Lyophilized powder stored dry at -20°C can retain potency for considerably longer. Turbidity, color change, or particulates are signs of degradation.
Does BPC-157 need to be kept cold before reconstitution?
Lyophilized BPC-157 is more stable than the reconstituted form but is best stored at -20°C for long-term preservation and at 2-8°C for short-term use. Repeated freeze-thaw cycles degrade the peptide. Allow the vial to reach room temperature before reconstituting to minimize condensation inside the vial.
Is oral BPC-157 equivalent to injectable BPC-157?
Animal studies have tested oral BPC-157 for GI-related endpoints with some positive results, but systemic bioavailability of orally administered peptides is generally very low due to GI proteolysis. For musculoskeletal or systemic endpoints, injectable routes are pharmacologically more defensible. Direct comparative human data do not exist.
What are the known risks of BPC-157 injections?
No human clinical safety trial has been completed and published. Known risks from self-reporting include injection-site reactions, nausea, and dizziness. Theoretical concerns include effects on angiogenesis and potential tumor-promoting activity given BPC-157's pro-angiogenic mechanism, though this has not been observed in animal studies at therapeutic doses.
How do you read a BPC-157 COA to verify purity?
A credible COA should report HPLC purity (look for greater than 98%), mass spectrometry (MS) confirming molecular weight of 1419.5 Da for the free acid form, and water content by Karl Fischer titration. The COA should name a third-party analytical laboratory. Reject any COA that reports only "greater than 95%" with no method stated or no lab name.
Can you use sterile water instead of bacteriostatic water for BPC-157?
Sterile water can be used, but bacteriostatic water (which contains 0.9% benzyl alcohol as a preservative) extends the usable life of the reconstituted solution by inhibiting microbial growth. If you use sterile water, the reconstituted vial should be used within 24 hours and any remainder discarded.
Sources
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632.
- Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Current Medicinal Chemistry. 2012;19(1):126-132.
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. PMC4264543.
- Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European Journal of Pharmacology. 2007;570(1-3):212-221.
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159.
- World Health Organization. Benzyl Alcohol: Safety Evaluation. International Programme on Chemical Safety. WHO Food Additives Series 46. 2001.
- United States Pharmacopeia. USP General Chapter 1 Injections and Implanted Drug Products. USP-NF Online. 2024.
- Bhasin S, Cunningham G
Related peptide guides